X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs BIOCON LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA BIOCON LTD CIPLA/
BIOCON LTD
 
P/E (TTM) x 43.4 36.7 118.4% View Chart
P/BV x 3.6 4.9 73.4% View Chart
Dividend Yield % 0.4 1.5 23.6%  

Financials

 CIPLA   BIOCON LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
BIOCON LTD
Mar-16
CIPLA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs622496 125.5%   
Low Rs458397 115.6%   
Sales per share (Unadj.) Rs181.9174.3 104.4%  
Earnings per share (Unadj.) Rs12.944.8 28.7%  
Cash flow per share (Unadj.) Rs29.356.9 51.5%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.41.1 33.0%  
Book value per share (Unadj.) Rs155.7202.8 76.8%  
Shares outstanding (eoy) m804.51200.00 402.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.6 116.0%   
Avg P/E ratio x42.010.0 421.5%  
P/CF ratio (eoy) x18.47.8 235.1%  
Price / Book Value ratio x3.52.2 157.7%  
Dividend payout %15.511.2 139.3%   
Avg Mkt Cap Rs m434,51689,220 487.0%   
No. of employees `00023.04.4 521.9%   
Total wages/salary Rs m26,3386,363 413.9%   
Avg. sales/employee Rs Th6,349.17,894.5 80.4%   
Avg. wages/employee Rs Th1,143.01,441.2 79.3%   
Avg. net profit/employee Rs Th449.32,029.7 22.1%   
INCOME DATA
Net Sales Rs m146,30234,854 419.8%  
Other income Rs m2,287845 270.6%   
Total revenues Rs m148,58935,699 416.2%   
Gross profit Rs m24,7588,200 301.9%  
Depreciation Rs m13,2292,423 546.0%   
Interest Rs m1,594102 1,562.5%   
Profit before tax Rs m12,2226,520 187.4%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m1,7982,569 70.0%   
Profit after tax Rs m10,3548,961 115.5%  
Gross profit margin %16.923.5 71.9%  
Effective tax rate %14.739.4 37.3%   
Net profit margin %7.125.7 27.5%  
BALANCE SHEET DATA
Current assets Rs m87,37039,932 218.8%   
Current liabilities Rs m33,08116,276 203.2%   
Net working cap to sales %37.167.9 54.7%  
Current ratio x2.62.5 107.7%  
Inventory Days Days8754 162.4%  
Debtors Days Days6286 72.3%  
Net fixed assets Rs m111,56739,101 285.3%   
Share capital Rs m1,6091,000 160.9%   
"Free" reserves Rs m123,64538,591 320.4%   
Net worth Rs m125,25440,556 308.8%   
Long term debt Rs m36,45420,724 175.9%   
Total assets Rs m209,53284,816 247.0%  
Interest coverage x8.764.9 13.4%   
Debt to equity ratio x0.30.5 57.0%  
Sales to assets ratio x0.70.4 169.9%   
Return on assets %5.710.7 53.4%  
Return on equity %8.322.1 37.4%  
Return on capital %8.519.0 44.8%  
Exports to sales %34.230.7 111.3%   
Imports to sales %8.320.4 40.9%   
Exports (fob) Rs m50,05010,717 467.0%   
Imports (cif) Rs m12,2037,105 171.7%   
Fx inflow Rs m51,06611,789 433.2%   
Fx outflow Rs m17,6788,393 210.6%   
Net fx Rs m33,3883,396 983.2%   
CASH FLOW
From Operations Rs m23,8245,264 452.6%  
From Investments Rs m-13,127-9,540 137.6%  
From Financial Activity Rs m-13,23910,867 -121.8%  
Net Cashflow Rs m-2,4786,591 -37.6%  

Share Holding

Indian Promoters % 16.0 40.4 39.6%  
Foreign collaborators % 20.8 20.6 101.0%  
Indian inst/Mut Fund % 12.2 8.4 145.2%  
FIIs % 23.7 10.7 221.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.9 131.7%  
Shareholders   161,166 109,995 146.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Consumer Durables Stocks Drag(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are trading above the dotted line. Except stocks in the consumer durables sector.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 23, 2017 03:36 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS